TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study
Yung-Jue Bang, Toshimi Takano, Chia-Chi Lin, Adedigbo Fasanmade, Huyuan Yang, Hadi Danaee, Takayuki Asato, Thea Kalebic, Hui Wang, Toshihiko Doi
Cancer Res Treat. 2018;50(2):398-404.   Published online 2017 May 10     DOI: https://doi.org/10.4143/crt.2017.074
Citations to this article as recorded by Crossref logo
Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential
Claudia Ceci, Pedro Miguel Lacal, Grazia Graziani
Pharmacology & Therapeutics.2022; 236: 108106.     CrossRef
Asia‐Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo
Karthik Venkatakrishnan, Neeraj Gupta, Patrick F. Smith, Tiffany Lin, Neil Lineberry, Tatiana Ishida, Lin Wang, Mark Rogge
Clinical Pharmacology & Therapeutics.2022;[Epub]     CrossRef
Research Progress of Antibody–Drug Conjugate Therapy for Advanced Gastric Cancer
Na Wang, Qingyun Mei, Ziwei Wang, Lu Zhao, Dou Zhang, Dongying Liao, Jinhui Zuo, Hongxia Xie, Yingjie Jia, Fanming Kong
Frontiers in Oncology.2022;[Epub]     CrossRef
Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development
Davinder Singh, Divya Dheer, Abhilash Samykutty, Ravi Shankar
Journal of Controlled Release.2021; 340: 1.     CrossRef